Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
Araki, Kazuhiro, Ito, Yoshinori, Fukada, Ippei, Kobayashi, Kokoro, Miyagawa, Yoshimasa, Imamura, Michiko, Kira, Ayako, Takatsuka, Yuichi, Egawa, Chiyomi, Suwa, Hirofumi, Ohno, Shinji, Miyoshi, YasuoVolume:
18
Language:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-018-4888-2
Date:
December, 2018
File:
PDF, 736 KB
english, 2018